21 minutes agoA Kosovar, U.S. study director who testified to the success of remdesiviviritri vs. Coronavirus
Periskopi(6 years ago)
(6 years ago)Kosovar, who had gone to the US during the war, led the clinical part of the latest US study, which provided the most convincing evidence of the effect of anti-virus therapy on COVID. This study, the youngest and most reliable, supports organization, structure, and the number of patients that dealt with the Reddesivir effect, was released on Wednesday. [...]
Kosovar, who had gone to the US during the war, led the clinical part of the latest US study, which provided the most convincing evidence of the effect of anti-virus therapy on COVID.
This study, the youngest and most reliable, supports organization, structure, and the number of patients that dealt with the Reddesivir effect, was released on Wednesday. It was sponsored by the National Institute for Allergy and Infectious Disease (NIAID), part of the US National Health Institute (NIH). And his pharmaceutical aspect was led by Dr. Zana Blacu-Tanushi, originally from Pristina, reports “ilypress”.
Blacku-Tanushi works as clinical pharmacist in the field of scientific research in medicine at the National Health Institute's clinical center (NIH).
According to her, while the results are still preliminary and should be done full analysis of all the data, this is a promising step.
The study started on February 21st and included 1063 in 68 countries in the United States, Europe and Asia. The security and testing monitoring board during the study informed researchers on April 27th that the remdesiviri was better than placebo.
